GnRH-I agonists inhibited epidermal growth factor- or insulin growth factor-stimulated prostate cancer cell proliferation, and induced the apoptosis of the cancer cells in conditions of serum deprivation [9], [10]. Here, GNRH1 is linked to prostate carcinoma.